Time-Resolved and Tissue-Specific Systems Analysis of the Pathogenesis of Insulin Resistance by Kleemann, Robert et al.
Time-Resolved and Tissue-Specific Systems Analysis of
the Pathogenesis of Insulin Resistance
Robert Kleemann
1,2,4*, Marjan van Erk
3, Lars Verschuren
1,2, Anita M. van den Hoek
1, Maud Koek
6,
Peter Y. Wielinga
1,4, Annie Jie
1, Linette Pellis
3, Ivana Bobeldijk-Pastorova
6, Thomas Kelder
5, Karin
Toet
1,4, Suzan Wopereis
3, Nicole Cnubben
3, Chris Evelo
5, Ben van Ommen
3, Teake Kooistra
1
1Quality of Life, Vascular and Metabolic Disease, TNO, Leiden, The Netherlands, 2Department of Vascular Surgery, Leiden University Medical Center, Leiden, The
Netherlands, 3Quality of Life, Physiological Genomics, TNO, Zeist, The Netherlands, 4Top Institute Food and Nutrition, Wageningen, The Netherlands, 5Department of
Bioinformatics, Maastricht University, Maastricht, The Netherlands, 6Quality of Life, Analytical Research, TNO, Zeist, The Netherlands
Abstract
Background: The sequence of events leading to the development of insulin resistance (IR) as well as the underlying
pathophysiological mechanisms are incompletely understood. As reductionist approaches have been largely unsuccessful in
providing an understanding of the pathogenesis of IR, there is a need for an integrative, time-resolved approach to
elucidate the development of the disease.
Methodology/Principal Findings: Male ApoE3Leiden transgenic mice exhibiting a humanized lipid metabolism were fed a
high-fat diet (HFD) for 0, 1, 6, 9, or 12 weeks. Development of IR was monitored in individual mice over time by performing
glucose tolerance tests and measuring specific biomarkers in plasma, and hyperinsulinemic-euglycemic clamp analysis to
assess IR in a tissue-specific manner. To elucidate the dynamics and tissue-specificity of metabolic and inflammatory
processes key to IR development, a time-resolved systems analysis of gene expression and metabolite levels in liver, white
adipose tissue (WAT), and muscle was performed. During HFD feeding, the mice became increasingly obese and showed a
gradual increase in glucose intolerance. IR became first manifest in liver (week 6) and then in WAT (week 12), while skeletal
muscle remained insulin-sensitive. Microarray analysis showed rapid upregulation of carbohydrate (only liver) and lipid
metabolism genes (liver, WAT). Metabolomics revealed significant changes in the ratio of saturated to polyunsaturated fatty
acids (liver, WAT, plasma) and in the concentrations of glucose, gluconeogenesis and Krebs cycle metabolites, and branched
amino acids (liver). HFD evoked an early hepatic inflammatory response which then gradually declined to near baseline. By
contrast, inflammation in WAT increased over time, reaching highest values in week 12. In skeletal muscle, carbohydrate
metabolism, lipid metabolism, and inflammation was gradually suppressed with HFD.
Conclusions/Significance: HFD-induced IR is a time- and tissue-dependent process that starts in liver and proceeds in WAT.
IR development is paralleled by tissue-specific gene expression changes, metabolic adjustments, changes in lipid
composition, and inflammatory responses in liver and WAT involving p65-NFkB and SOCS3. The alterations in skeletal
muscle are largely opposite to those in liver and WAT.
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Introduction
Diabetes mellitus type 2 (DM2) is a metabolic disorder that is
primarily characterized by insulin resistance (IR), relative insulin
deficiency and hyperglycemia. DM2 is rapidly increasing in the
developed world, and there is some evidence that this pattern will
be followed in much of the rest of the world in the coming years
[1].
IR is the condition in which regular amounts of insulin are
inadequate to produce a normal insulin response in liver, adipose
and muscle cells, and a key factor in the pathogenesis of DM2 [2].
The defects in insulin action in glucose metabolism include
deficiencies in the ability of the hormone to suppress glucose
production by the liver and to mediate glucose uptake and
metabolism in insulin sensitive peripheral tissues (skeletal muscle
and adipose tissue). The genetic and molecular bases for these
reductions in insulin sensitivity are not fully understood.
IR is positively associated with visceral adiposity, i.e. a high
degree of fatty tissue underneath the abdominal muscle wall [1].
Although epidemiological correlations are established, the cellular
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unknown. Growing evidence associates a chronic, subacute
inflammatory state with the development of obesity and IR
[1,3]. Mediators of inflammation and the acute-phase response are
positively associated with a risk of future IR/DM2 in humans [4]
and can induce the disease in rodent models [5,6], suggesting that
low-grade inflammation precedes and triggers the development of
IR/DM2. Indeed, proinflammatory cytokines such as TNFa,
MCP-1, MIF can cause IR and anti-inflammatory medications
may reverse it [5–9], and pathways involving the induction of
nuclear factor-kB (NF-kB) or suppression of cytokine signaling
(SOCS) proteins may be involved in the pathogenesis [8,10]. An
important unsolved issue is the origin of the inflammatory
mediators and what stresses cause the activation of inflammatory
pathways. There is ample evidence that the inflammatory response
that emerges in the presence of obesity is triggered by metabolic
dysregulation and resides predominantly in white adipose tissue
(WAT), although other metabolically critical sites, particularly the
liver, might also be involved [3]. Recent data from experimental
models also indicate that metabolic stress is critical to the initiation
and integration of this network of inflammatory pathways in
obesity and DM2 [2,3], but the understanding of the exact link
between nutrient excess and the emerging inflammatory response
is still incomplete.
Because studies in humans can never be as targeted as the
experimental manipulations achievable in animal models, patho-
physiological and mechanistic information is often obtained from
studies in mice that are fed a high fat diet (HFD). A frequent
limitation of these studies is that they are not time-resolved and
that they, inherently to this set-up, provide information of a single
time point or disease stage. Consequently, remarkably little is
known about the line of events and tissue-specificity of HFD-
induced IR and the dynamics of the changes in key metabolic
processes.
To gain more insight into the disease process, we herein studied
the association between excessive intake of dietary fat (causing
metabolic dysregulation and metabolic stress) and the develop-
ment of obesity and IR, using an integrative time-resolved
approach. We systematically established the sequence of events
leading to metabolic stress, tissue-specific inflammation, abdom-
inal adiposity and organ-specific (liver, WAT, skeletal muscle)
development of IR. HFD-treated ApoE*3-Leiden (E3L) mice were
used because of the humanized lipoprotein metabolism and the
translational value of this model for the human situation [11]. An
important goal of the study was to identify – by combining
transcriptomics with metabolomics and a comprehensive free fatty
acid analysis – the molecular entities showing differential
expression in liver or periphery (WAT, muscle) during initiation
and progression of IR development. Particular emphasis was put
on the biological processes and molecular networks that mediate
metabolic dysregulation and that are associated with pathophys-
iological changes in liver and WAT, viz. the time course of
changes in lipid and carbohydrate metabolism linked to
inflammatory responses. This integrative approach provided solid
evidence for and insight into the time-dependent, tissue-specific
development of IR and the associated series of parallel and
successive alterations in metabolic and inflammatory processes.
Materials and Methods
Animals and Diets
All animals received humane care according to the criteria
outlined in the ‘‘Guide for the Care and Use of Laboratory
Animals’’ prepared by the National Academy of Sciences and
published by the National Institutes of Health (NIH). All animal
experiments were approved by an independent institutional ethical
committee on animal care and experimentation (Dierethische
Commissie DEC, Zeist, The Netherlands). Male ApoE*3-Leiden
transgenic (E3L) mice (n=100 in total) were from TNO-
BioSciences, Gaubius Laboratory, Leiden, The Netherlands. Mice
were housed in groups (n#4) wire-topped Macrolon cages and had
access to water and diet ad libitum. Prior to high fat diet treatment
animals received standard laboratory chow (Sniff R/M H chow,
Research Diets, Uden, The Netherlands).
At the start of the experimental treatment period, E3L mice
were 12 weeks of age. A tail blood sample was taken after 5 h of
fasting in all animals. Then, animals were subjected to a glucose
tolerance test (GTT) at t=22.5 weeks, i.e. an intraperitoneal
injection of glucose (2 g/kg body weight) to determine their
individual ability to clear glucose. After a recovery period of 2.5
weeks (from -2.5 weeks to t=0), animals were fed a high-fat diet
(HFD) containing 24% w/w fat (beef tallow) equaling provision of
45% energy (diet 4031.05; Hope Farms, Woerden, The Nether-
lands). The HFD is composed of (in w/w) 24% fat (12% saturated,
10% monounsaturated and 1% polyunsaturated fatty acids, 21%
protein and 35% carbohydrates (19% sugars); the diet composition
of the manufacturer is provided as Table S1) for 12 weeks. Tail
blood samples were collected after 5 h of fasting, and plasma was
stored at 280uC until use. Groups of n=15 animals (per time
point) were subjected to a second i.p. GTT to assess the individual
disease status at t=0, and after 1 w, 6 w, 9 w and 12 w of HFD
feeding. Three days after this second GTT, animals were fasted for
5 hours and euthanized with CO/CO2 to collect tissues (viz., liver,
adipose tissue, and skeletal muscle) for transcriptomics, metabo-
lomics and immunohistochemical analyses, i.e. Oil-Red O-staining
for analysis of lipid droplets in cross-sections of liver and
hematoxylin phloxine saffron (HPS)-staining for morphological
analysis of adipocytes in WAT, essentially as described [5]. Tissues
were snap-frozen immediately in liquid nitrogen, and stored at
280uC until use. Parallel to this time course experiment,
additional groups of n=6–9 animals each were subjected to
hyperinsulinemic, euglycemic clamp analysis with radioactive
tracers to assess tissue-specific insulin sensitivity at t=0, 6 w and
12 w of HFD treatment.
Analysis of Plasma Lipids, Lipoproteins, and Plasma
Inflammation Markers
Total plasma cholesterol and triglyceride levels were measured
after 5 hours of fasting, using kits No. 11489437 and 11488872
(Roche Diagnostics, Almere, The Netherlands), respectively, and
NEFA with kit WAKO 999-75406 (FFA test NEFA-HR,
Instruchemie, Delfzijl, The Netherlands). For lipoprotein profiles,
pooled plasma was fractionated using an A ¨KTA FPLC system
(Pharmacia, Roosendaal, The Netherlands) [12]. The plasma
levels of adiponectin, leptin, E-selectin, VCAM-1 (all R&D
Systems Europe Ltd., Abington, UK), SAA (Biosource), vWF
(in-house assay) and fibrinogen (in-house assay) were determined
by ELISA as reported [12,13].
Glucose Tolerance Test and Hyperinsulinemic Euglycemic
Clamp Analysis
Glucose tolerance tests were performed after a 5h-fasting period.
Mice were injected intraperitoneally with glucose (2 g/kg body
weight) and blood glucose levels were monitored for 120 minutes
using a hand-held glucose analyzer (FreeStyle, Disectronics,
Vianen, The Netherlands) at t=0, 15 min, 30 min, 60 min and
120 min after glucose injection, essentially as described [5].
Systems Analysis of IR
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described [5] (n=6–9 animals per group). In short, after an
overnight fast, mice were anesthetized with 6.25 mg/kg Acepro-
mazine, (Sanofi sante animale, Libourne Cedex, France),
6.25 mg/kg Midazolam (Roche, Mijdrecht, The Netherlands)
and 312.5 mg/kg Fentanyl (Janssen-Cilag, Tilburg, the Nether-
lands) and an infusion needle was placed in one of the tail veins.
Subsequently, a bolus of insulin (4.1 mU Actrapid, Novo Nordisk,
Chartres, France) was given, and a hyperinsulinemic euglycemic
clamp was started with a continuous infusion of insulin (6.8 mU)
and a variable amount of 12.5% D-glucose (in PBS) to maintain
blood glucose levels at about 7.5 mmol/L. Blood samples were
taken every 10 min and plasma glucose levels were measured
using a hand-held glucose analyzer (FreeStyle, Disectronics,
Vianen, The Netherlands) allowing to adapt glucose infusion rates
accordingly [5].
RNA Extraction for Microarray Analysis
Total RNA was extracted from individual tissues (liver, muscle,
WAT (epidydimal)) using RNAzol (Campro Scientific, Veenen-
daal, The Netherlands) and glass beads [14]. The integrity of each
RNA sample obtained was examined by Agilent Lab-on-a-chip
technology using the RNA 6000 Nano LabChip kit and a
bioanalyzer 2100 (Agilent Technologies, Amstelveen, The Nether-
lands). RNA preparations were considered suitable for array
hybridization only if samples showed intact 18S and 28S rRNA
bands, and displayed no chromosomal peaks or RNA degradation
products (RNA Integrity Number .8.0) [15].
The One-Cycle Target Labeling and Control Reagent kit
(Affymetrix #900493) and the protocols established by Affymetrix
were used to prepare biotinylated cRNA (from 5mg of total RNA)
for microarray hybridization (n=8 for each tissue at each time
point). The quality of intermediate products (i.e., biotin-labeled
cRNA and fragmented cRNA) was again controlled using the
RNA 6000 Nano Lab-on-a-chip and bioanalyzer 2100. Two
muscle-tissue RNA samples (one t=0 sample and one t=6 weeks
sample) did not pass the Quality Control check and were excluded
from further analysis. Microarray analysis was carried out using an
Affymetrix technology platform and Affymetrix GeneChipH
mouse full genome 430 2.0 arrays (45,037 probe sets; 34,000
mouse genes). Briefly, fragmented cRNA was mixed with spiked
controls, applied to Affymetrix Test chips, and good quality
samples were then used to hybridize with murine GeneChipH 430
2.0 arrays. The hybridization, probe array washing and staining,
and washing procedures were executed as described [15], and
probe arrays were scanned with a Hewlett-Packard Gene Array
Scanner (Leiden Genome Technology Center, Leiden, The
Netherlands).
Gene Expression Data Analysis
Quality control of microarray data was performed using
BioConductor packages (including simpleaffy and affyplm,
through the NuGO pipeline that is available as a Genepattern
procedure on http://nbx2.nugo.org [16].
Two microarrays from WAT (week 1 and week 12) and one
microarray from skeletal muscle (week 6) did not pass quality
control criteria. The final microarray dataset consisted of 40
samples from liver, 38 samples from WAT and 37 samples from
muscle according to procedures developed for this purpose [16].
Microarray data have been submitted to ArrayExpress (http://
www.ebi.ac.uk/microarray-as/ae/).
The present study represents also one of the core studies of
NuGO. The transcriptomics datasets are currently used by other
researchers as announced recently (e.g. follow-up studies analyzing
the various adipose tissue depots) [17].
For each tissue, raw signal intensities (from CEL files) were
normalized using the GCRMA algorithm (gc-rma slow). Probesets
were remapped and annotated into Entrez gene-ids using the
custom MBNI CDF-file, version 9.0.1. This resulted in expression
values for 16297 genes, represented by unique Entrez gene-ids.
Genes were filtered on expression value above 5 in at least 4
samples, resulting in a set of 12251 genes for liver, 12492 genes for
WAT and 10776 genes for muscle. Expression data were log-
transformed (base 2). In muscle a batch effect of the two different
labeling days was observed and a batch correction was performed.
Expression values of individual samples at weeks 1, 6, 9 and 12
were corrected for mean expression in samples of week 0, resulting
in 2log ratios of expression compared to mean expression at week
0. T-profiler was used to assess enrichment of functional groups of
genes (based on Gene Ontology) for all samples [18]. For each
tissue, enriched functional groups were selected based on
significant enrichment (t-score .|4|) in at least 5 samples of at
least one time point. Next, a union list of enriched functional
groups in the different tissues was submitted to hierarchical
clustering (Genepattern, Broad Institute, MIT, USA). PathVisio
[19] was used to visualize biological processes modulated by HFD
in WAT and liver. Networks representing biological processes and
their genes were generated based on pathways from the Kegg
(www.genome.jp/kegg) and WikiPathways (www.wikipathways.
org) pathway archives [20] (Version Feb. 2009) and visualized
using Cytoscape and the VistaClara plugin [21]. Nodes in the
network represent either a biological process or a gene. An edge is
present between a process-node and gene-node when the gene
plays a role in the biological process. The nodes representing genes
that had no significant change (ANOVA q,0.01) in expression
were filtered out. Thus connections between pathways only consist
of genes that are present in both pathways and that showed a
significant change over time. The size of nodes representing a
biological process was scaled by a z-score representing enrichment
of significant genes (ANOVA q,0.01).
Microarray gene expression data were confirmed by quantita-
tive real-time PCR for a selection of genes using established
protocols and primer/probe sets [14,15].
Analysis of Free Fatty Acids
5 ml of plasma or 5 mg lyophilized WAT or 5 mg lyophilized
liver were used for a basic analysis of free fatty acids. Plasma and
tissue homogenates were prepared as described [22] with the
change that isopropanol instead of methanol was used for
extraction of lipids. Analysis of the fatty acids extracts was
according to the method reported by Pettinella and coworkers[23]
which involves derivatization of fatty acids with quaternary
ammonium, allowing an analysis of fatty acid derivatives in the
positive mode and the discrimination of n-3 and n-6 fatty acids.
Measurements were carried out using a ThermoElectron LTQ-
Orbitrap (LC-MS), equipped with a ThermoElectron Accela
UHPLC with autosampler and column-oven (ThermoElectron,
Breda, The Netherlands). 1.5 mL of the derivatized extract
(maintained at 20uC in the autosampler) was injected onto a
C8 column (Waters Acquity C8 1.7 mm particle size,
2.1 mm6100 mm). Biomolecules were separated at a flow-rate
of 500 mL/min using a acetonitrile–aqueous formic acid gradient.
Detection was performed using electrospray in the positive mode
and data were processed using the LC Quan software (Thermo-
Electron, Breda, The Netherlands) for peak integration, calibra-
tion and quantification following the protocol of the manufacturer.
Systems Analysis of IR
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To analyze metabolite changes in liver, a recently developed
GCxGC-MS-based method was followed [24]. In short, for
sample preparation, the liver samples were freeze-dried overnight
and homogenized. 10 mg aliquots of the liver samples were
weighed and placed inside a two ml Eppendorf tube. After
addition of 10 ml of IS mix 1 and 500 ml of methanol/water 4:1 v/
v, all samples were sonicated for 30 min and subsequently
centrifuged for 10 min at 10000 rpm. The supernatants were
transferred to autosampler vials and subsequently dried under
nitrogen flow. Then 30 ml ethoxyamine hydrochloride was added
and the samples were oximated for 90 min at 40uC on a tube
roller mixer placed inside a stove. Subsequently, 100 ml of MSTFA
was added and samples were silylated for 50 min at 40uCo na
tube roller mixer. Finally the samples were centrifuged for 20 min
at 3500 rpm prior to injection to remove debris.
The GCxGC-MS measurements were performed as described
[24]. Briefly, derivatized samples were analyzed with an Agilent
6890 gas chromatograph fitted with a dual stage, four jet (two
liquid nitrogen cooled and two hot gas jets) cryogenic modulator
and a secondary oven (LECO, Mo ¨nchengladbach, Germany), and
coupled to a time-of-flight mass spectrometer (Pegasus III, LECO).
The configuration of the first (1D) and second dimension (2D)
column and the method parameters were optimized [24]. A
30 m60.25 mm I.D.60.25 mm forte BPX-50 column (SGE
Europe, Milton Keynes, UK) was used as the first dimension
column and a 2 m60.32 mm I.D.60.25 mm forte BPX5 column
(SGE Europe) as the second dimension column.
1-ml aliquots of the derivatized extracts were injected using
PTV-injection (Gerstel CIS4 injector) in the splitless mode. The
temperature of the PTV was 70uC during injection, and 0.6 min
after injection the temperature was raised to 300uC at a rate of
2uC per second and held at 300uC for 20 minutes. The initial GC-
oven temperature was 70uC, 3 min after injection the temperature
was raised to 300uC with a rate of 5 uC/min and held at 300uC for
10 min. The temperature offset of the secondary oven and
modulator compared to the GC oven were set at +30uC and
+40uC, respectively. The modulation time was 6 seconds, with the
hot pulse time set at 1 second. Helium was used as carrier gas and
the analyses were carried out in constant pressure mode at
300 kPa. The MS transfer line was set at 325 uC and the ion
source temperature was kept at 280uC. The detector voltage was
set at 1600 V and the data acquisition rate was 75 Hz. The
Chemstation software (Version E02.00.493, Agilent Technologies)
was used for processing of the data. A target table was constructed
using an in-house library of over 400 metabolites containing their
spectra and retention times.
Western Blot Analysis
Tissue extracts from liver, WAT and skeletal muscle were
prepared in presence of proteinase inhibitors[25] and Western blot
analyses was performed essentially as described previously[26]
using antibodies specific for mouse SOCS3 (rabbit anti-SOCS3;
ab3693; Abcam, Cambridge, UK) and PTP1B (rabbit anti-
PTP1B; ab52650; Abcam, Cambridge, UK) and b-actin (anti-b-
actin; sc-1615; Santa Cruz Biotechnology, Heerhugowaard, The
Netherlands) for standardization of protein expression levels
[27,28].
Secondary antibodies were obtained from Santa Cruz Biotech-
nology and Pierce (Etten-Leur, The Netherlands) and immuno-
blots were visualized and quantified using the Super Signal West
Dura Extended Duration Substrate (Perbio Science, Etten-Leur,
The Netherlands), LabWorks 4.6 software and a luminescent
image workstation (UVP, Cambridge, UK) [28]. SOCS3 and
PTP1B protein expression data are reported as band intensity of
immunostaining values (arbitrary units) as described by Guerra et
al [29].
Analysis of NF-kB Activity in Liver
To determine active p65-NF-kB activity in livers, tissue
homogenates were prepared using the Nuclear Extract Kit
(no. 40010, Active Motif, Rixensart, Belgium) and the protein
content of the samples was determined[30] by the method of
Bradford. Equal amounts of protein were used in the NF-kB
TransAM transcription factor assay kit no. 40097 (Active Motif,
Rixensart, Belgium). The assays were performed according to the
manufacturer’s instructions. Briefly, the amount of active tran-
scription factor present in each sample was determined by
measuring the binding of the active transcription factor to a
consensus sequence in the presence of either a competitive or a
mutated (non-competitive) oligonucleotide to correct for non-
specific binding. Data are presented as relative units.
Biochemical Analyses in Tissue Hepatic Homogenates
To determine the hepatic triglyceride content, liver biopsies
were homogenized and the protein content was determined. 2 mg
of cholesterol acetate was added as an internal standard. Lipids
were extracted according to the Bligh and Dyer method [31]. The
neutral lipids were separated by high performance thin layer
chromatography on silica-gel-60 pre-coated plates and lipids were
quantified by scanning the plates with a Hewlett Packard Scanjet
4c and subsequent computerized analysis of the density areas [14].
Statistical Analysis
Statistical analysis was performed using Graphpad Prism 4.0
and SPSS 17.0. Plasma parameters (triglycerides, FFA, fibrinogen,
SAA, VCAM-1, E-selectin, vWF, adiponectin) and body weight
were determined in the group of mice (n=15) that was sacrificed
after 12 weeks of diet-feeding. Parameters requiring large volumes
of plasma/serum for their quantification (cholesterol, ketone
bodies, ALAT, leptin, glucose, insulin) were determined in
plasma/serum collected at sacrifice. Changes over time (versus
baseline t=0) were statistically analyzed by with One-way
ANOVA (repeated measures for within subject samples) and
LSD post-hoc, unless stated otherwise.
Results
Effect of HFD Feeding on Adiposity and Plasma Lipids
Groups (n=15 animals each) of E3L mice were fed HFD for 12
weeks. Food intake, body weight, plasma lipids and circulating
tissue-specific inflammation markers were analyzed over time.
Table 1 provides an overview of the baseline (t=0), intermediate
(t=6 w) and end point (t=12 w) levels.
There was a gradual increase in body weight, resulting in a
significant difference in body weight between t=0 (29.960.5 g)
and t=6 w (35.461.0 g; P,0.001). Body weight at the end of the
treatment period was 37.561.1 g. The average food intake per
mouse was 3.9 g per day.
Analysis of the mass of subcutaneous, visceral and epididymal
fat pads of mice sacrificed at t=0 and in weeks 1, 6, 9 and 12 of
HFD feeding revealed a marked increase in adipose mass over
time for all three fat depots (Figure 1A). The epididymal fat mass
increased gradually over time, while the subcutaneous and visceral
depots mainly increased in the first week and in the period
between week 9 and 12.
The circulating leptin levels, which generally reflect adipose
mass and differentiation [32], paralleled the increases in fat and
Systems Analysis of IR
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(0.160.09 ng/ml) and increased strongly over time, reaching a
concentration of 8.461.3 ng/mL (P,0.01) in week 12 (Figure 1B).
Another adipokine, adiponectin, increased slightly but significantly
in the first 6 weeks (from 7.4760.48 mg/mL to 9.0360.39 mg/mL,
P,0.05), and remained at this elevated level from then on
(Table 1).
Baseline plasma cholesterol levels (2.1560.23 mM) increased
rapidly in response to HFD feeding to 5.560.32 mM (P,0.05) in
week 1, and remained at this elevated level until the end of the
study (5.9660.40 mM in week 12). Plasma triglyceride decreased
slightly within one week from 1.3760.08 mM to 1.0060.06 mM
(P,0.01) and then stayed at this level (0.9760.04 mM in week 12;
Table 1).
The plasma concentration of total free non-esterified fatty acids
(NEFAs) was not markedly affected: the NEFAs level in week 12
(1.0860.04 mM) was comparable to the baseline level
(1.0060.05 mM; Table 1). Plasma concentrations of ketone
bodies did not change until week 9, but dropped markedly
between week 9 and 12 (from 0.4060.08 mM to 0.2660.02 mM)
pointing to decreased b-oxidation of fatty acids.
HFD Feeding Alters Lipid Composition of Free Fatty Acids
We next assessed whether HFD feeding may induce changes in
the type of circulating fatty acids and thus may alter plasma lipid
composition. Analysis of saturated, monounsaturated and polyun-
saturated fatty acids by LC/MS revealed an important change in
their relative amounts during HFD treatment (Figure 2 and Table
S2). Stearic acid, a saturated fatty acid, and the monounsaturated
fatty acids oleic and eicosenic acid significantly increased over
time, while n-3 polyunsaturated fatty acids (PUFAs) such as alpha-
linolenic acid, stearidonic acid, eicosatetraenoic acid and eicosa-
pentaenoic acid (EPA), all of which considered to be beneficial for
health, consistently decreased with HFD feeding. Also, the plasma
concentration of several n-6 PUFAs, including linoleic acid,
gamma-linolenic acid and adrenic acid, significantly and consis-
tently declined during the 12 weeks HFD period (Table S2).
HFD Feeding Induces Chronic Low-Grade Inflammation
The plasma levels of the liver-derived inflammation markers
serum amyloid A (SAA) and fibrinogen gradually increased during
the study period. SAA levels were very low at t=0 (0.160.1 mg/
mL) and reached concentrations of 1.460.4 mg/mL in week 12
(P,0.01), whereas fibrinogen concentrations increased from
2.360.2 mg/mL to 3.960.3 mg/mL during the same period
(P,0.001), with most pronounced increases occurring after week 6
(Table 1). Of note, SAA and fibrinogen transiently peaked in week
1 (3.361.7 mg/mL) and week 3 (3.560.3 mg/mL), respectively,
indicating an acute-type inflammatory response to HFD (data not
Table 1. Body weight, plasma lipids and inflammation
markers over time.
t=0 t=6w t=12w
Body weight [g] 29.960.5 35.461.0*** 37.561.1***
Cholesterol [mM] 2.1560.23 5.2960.35*** 5.9660.40***
Triglyceride [mM] 1.3760.08 0.9360.04*** 0.9760.04***
NEFAs [mM] 1.0060.05 0.8460.03* 1.0860.04
Ketone bodies [mM] 0.4760.05 0.4860.04 0.2660.02***
SAA [mg/ml] (L; A) 0.1060.10 0.4760.27 1.4060.36**
Fibrinogen [mg/mL] (L) 2.2960.16 2.8960.18 3.9460.34***
ALAT [U/mL] (L) 114626 82614 99622
VCAM-1 [mg/ml] (V) 2.5460.08 3.3960.08*** 3.5060.20***
E-selectin [ng/mL] (V) 131.567.4 160.3617.6* 153.9610.0
vWF [% of pool] (V) 189622 304638 417658***
Leptin [ng/ml] (A) 0.1060.09 2.2260.73 8.4461.32***
Adiponectin [mg/mL] (A) 7.4760.48 9.0360.39* 9.4460.59**
Lipids and inflammation markers determined in EDTA plasma obtained by tail
bleeding after 5 h of fasting. Values of the time points t=0, 6 and 12 weeks are
shown. Letters in brackets indicate the main origin of the inflammation markers:
liver (L), adipose tissue (A) or vasculature (V). Values are means 6 SEM.
Significance of post-hoc analysis is indicated * P,0.05, **P,0.01, ***P,0.001
(as compared to the starting level at t=0).
doi:10.1371/journal.pone.0008817.t001
Figure 1. Fat mass over time. (A) Bars represent total fat mass
subdivided into the epididymal, subcutaneous and visceral adipose
tissue depots. Groups of n=15 animals were sacrificed at the time
points indicated to determine adipose mass of the various depots. Data
are presented as means 6 SEM. *P,0.05 indicates significance
compared to t=0 for each type of adipose tissue depot or the total
fat mass. (B) Plasma leptin levels over time presented as means6SEM.
*P,0.01 compared to t=0.
doi:10.1371/journal.pone.0008817.g001
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did not change and remained at a constant level (Table 1).
VCAM-1 and E-selectin, markers for vascular inflammation
and endothelial dysfunction, responded rapidly to HFD feeding
and reached maximal plasma levels within 3 weeks: VCAM-1
increased from 2.560.1 mg/mL at t=0 to 3.460.2 mg/mL in
week 3 and E-selectin rose from 13267 ng/mL at t=0 to
15866 ng/mL in week 3. The vascular endothelium activation
marker, von Willebrand factor (vWF) increased continuously
during HFD treatment, from 189622% at t=0 to 417658% in
week 12 (P,0.001; Table 1).
Together, HFD feeding caused metabolic as well as inflamma-
tory changes over time as reflected by dyslipidemia, pronounced
marked changes in fatty acid composition, and elevated levels of
circulating inflammation markers.
Effect of HFD on Metabolic Parameters and Glucose
Tolerance
Fasting plasma insulin and glucose levels were determined
after a 5-h fasting period at the time points specified in
Figure 3A/B. Insulin levels did not significantly change over
the first 6 weeks and remained close to the t=0 value of
1.160.4 mM; then, plasma insulin started to increase up to
1.360.2 mM in week 9 and 1.660.2 mM (P,0.05) in week 12.
A similar, but delayed, pattern was seen for glucose: fasting
plasma glucose levels did not significantly change between t=0
(8.960.6 mM) and week 9 (9.560.6 mM), but increased
significantly thereafter, reaching 13.060.5 mM (P,0.01) at 12
weeks of HFD. Fasting insulin and glucose concentrations were
used to calculate the Homeostatic Model Assessment of Insulin
Resistance (HOMA) index. HOMA remained unchanged until
week 6 and increased then gradually (2.1-fold increase in week
12; P,0.01).
Glucose tolerance tests (GTT) were performed in each animal
prior to inclusion into the study (at t=22.5 weeks; data not
shown) and 3 days before sacrifice (i.e. at 0, 1, 6, 9, 12 weeks of
HFD feeding; Figure 3C). Prior to HFD treatment, mice were
able to fully clear a bolus of glucose within 120 min (Figure 3C).
This ability was lost already after 1 week of HFD feeding, and
mice developed increasing glucose intolerance with prolonged
HFD feeding. In accordance herewith, the area under the curve
(AUC) increased over time and was significantly higher
compared to t=0 at all time points analyzed, except week 6
(Figure 3D).
Time Course of Insulin Resistance (IR) Development in
Liver, WAT, and Muscle by Clamp Analysis
To determine when and to what extent liver, adipose and
muscle tissues become insulin insensitive, hyperinsulinemic-
euglycemic clamp analysis was performed at t=0, 6 and 12
weeks. The glucose infusion rate (GIR), a measure of whole body
insulin sensitivity, was determined first. Consistent with a
progressive development of IR over time, the GIR tended
(P=0.13) to be lower in week 6 when compared to t=0
(Figure 4A) and became significantly reduced in week 12 (P,0.05).
The use of radioactive glucose tracers allowed us to determine
the sequence of IR development in liver, WAT and muscle by
analyzing the ability of insulin to shut down endogenous hepatic
glucose production (HGP) and to stimulate the glucose uptake into
adipose tissue and skeletal muscle.
HFD feeding alone reduced baseline endogenous HGP
significantly in week 6 and 12 (Figure 4B; left panel). The
application of hyperinsulinemic conditions almost fully shut
down HGP at t=0 demonstrating that the liver was insulin
sensitive prior to HFD feeding (Figure 4B; right panel). After 6
and 12 weeks of HFD feeding the inhibitory effect of insulin
became markedly weaker, clearly indicating a decreased insulin
sensitivity of the liver at these time points. Consistent with this,
the hepatic insulin sensitivity index (HISI) calculated from the
equation HISI=(HGPbasal - HGPhyper)/HGPbasal was mark-
edly reduced (by 40%; P,0.05) in week 6, pointing to hepatic
IR.
Figure 2. HFD feeding alters the relative amount of saturated, monounsaturated and polyunsaturated fatty acids. Free fatty acid
analysis of plasma. Representative fatty acids of the C18 category (stearic acid, oleic acid, alpha-linolenic acid and linoleic acid) are shown. Data
presented are relative amounts and values are means 6 SEM. *P,0.001.
doi:10.1371/journal.pone.0008817.g002
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8206145 nmol/mg tissue protein and 105627 nmol/mg tissue
protein, respectively (Figures 4C and D). 6 weeks of HFD feeding
not significantly affected glucose uptake into WAT and muscle.
After 12 weeks however, glucose uptake into WAT, but not
muscle, was strongly and significantly reduced (270637 nmol/mg;
P,0.05), clearly indicating that this tissue had become IR, notably
at a later time point than liver.
Figure 3. Effect of HFD feeding on fasting plasma insulin and glucose levels and glucose tolerance. Plasma insulin (A) and glucose (B)
levels determined after a 5 hr fasting period. A glucose tolerance test (GTT) (C) was performed 2.5 weeks prior to inclusion into the study (not shown)
and each animal underwent a second GTT, in week 0, 1, 6, 9, and 12 of HFD feeding (n=15 each). After a 5 h fast, animals received 2 g glucose/kg
body weight (i.p.). Glucose was recorded at the time points indicated and the area under the curve (AUC) (D) was calculated. Values are means 6
SEM. **P,0.01; *P,0.05
doi:10.1371/journal.pone.0008817.g003
Figure 4. Glucose tolerance test and hyperinsulinemic, euglycemic clamp analysis. In a parallel, independent animal experiment, HFD-fed
mice were subjected to hyperinsulinemic, euglycemic clamp analysis. (A) shows the glucose infusion rate (GIR) under hyperinsulinemic conditions.
Radioactive tracers allowed determining hepatic glucose production rate (HGP) (B) as well as the tissue-specific uptake of glucose into WAT (C) and
skeletal muscle (D). ‘Basal’ indicates prior to hyperinsulinemic clamp conditions and ‘hyper’ indicates hyperinsulinemic clamp conditions. Values are
means 6 SEM. *P,0.05 vs. t=0.
doi:10.1371/journal.pone.0008817.g004
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Metabolic Processes
To gain further insight into the time course and metabolic
processes underlying IR evolution, high quality RNA was
prepared from liver, WAT and skeletal muscle and subjected to
microarray analysis.
Microarray data were analyzed by hierarchical clustering of
enriched functional groups of genes (based on Gene Ontology) and
the major results are graphically illustrated in a heat map (Figure 5).
HFD elicited distinct changes in gene expression in liver, WAT and
muscle of E3L mice over time, with most changes in liver and WAT
being increases and those in skeletal muscles being decreases.
Typically, in the early stages, the expression of genes is often only
marginally modulated. With time, particularly when glucose
intolerance and adipose mass proceed and other exacerbating factors
may come into play, gene expression profiles become categorically
increased in liver and WAT while they decreased in skeletal muscle.
The liver is a key player in the control of whole body energy
metabolism by its ability to synthesize, oxidize, store, and
distribute the major sources of energy, glucose and fatty acids.
Accordingly, after starting the HFD feeding, the liver immediately
responds by up-regulating the expression of genes involved in
glucose metabolic processes, (cellular) carbohydrate metabolic
processes, fatty acid biosynthetic and metabolic processes, (cellular)
lipid metabolic processes, and lipid transport, while in WAT only
the expression of genes involved in (cellular) lipid metabolic
processes and lipid transport increase (Figure 5 and Figure S1). Of
note, fatty acid biosynthesis is upregulated in liver and downreg-
ulated in WAT, while fatty acid metabolism is upregulated in both
tissues, with WAT responding less strongly.
Strikingly, the above functional groups that are up-regulated in
liver, are down-regulated in muscle, albeit that the onset is more
slowly. This is most clear for lipid metabolism, which is positively
affected in liver already in week 1 and down-regulated in muscle from
week 6 onward (Figure 6). Specific for WAT, oxidoreductase activity
and endoplasmatic reticulum processes were upregulated at all time
points while opposite effects were found for liver and skeletal muscle.
Time-Resolved and Tissue-Specific Microarray Analysis of
Inflammatory Processes
A distinction also exists between the occurrence of hepatic
inflammation and the inflammation that arisesin WAT and muscle.
Hepatic acute-phase type responses and chronic inflammatory
responseswereincreasedasearlyasoneweekafterstartingtheHFD
feeding, but the acute forms of inflammation completely had
returned to control levels in week 9, whereas the chronic
inflammatory response decreased continuously, nearing control
t=0 values in week 12 (Figure 6). In WAT, however, the expression
of acute-phase response genes increased continuously over time,
whereas chronic inflammatory responses (e.g. the genes Ccl2 and
interleukin-1 receptor antagonist) increased later (. week 6),
reaching highest values in week 12 (Figure 6 and Figure 7, left
panel). Direct comparison of WAT and liver revealed that genes
encoding for PAI-1, MCP-1 and fibrinogen-a,-b and-c were
predominantly and almost exclusively increased in WAT (Figure 7).
Together, this demonstrates that HFD feeding evokes an acute-
type inflammatory response in liver and WAT, and a chronic
inflammatory response which declines in liver and increases in
WAT over time demonstrating that WAT is an important source
of inflammation in the long term disease progression.
In a more refined analysis of the inflammatory processes,
PathVisio results were combined with a network representation in
Cytoscape. In liver, the TNFalpha/NFkB signaling, MAPK
signaling and T cell signaling routes (Figure 8) and, in WAT,
the TGFbeta signaling, cell adhesion, Toll-like receptor signaling,
complement and coagulation cascades, IL-6 signaling as well as
inflammatory cytokine responses (Figure 9A) were stimulated by
HFD during the experimental period, indicating that distinct, yet
different, inflammatory processes and routes are triggered in the
two tissues. Assessment of p65-NFkB activity in liver homogenates
by TransAM analysis confirmed an increased activation of this
transcription factor over time (Figure 8).
Similarly as seen for the gene expression profiles for carbohy-
drate- and lipid-related processes, the acute phase and inflamma-
tory responses in muscle are opposite to and also slower in onset
than their counterparts in liver (Figures 5 and 6). Consistent with
this, among the processes downregulated in muscle are inflam-
matory response pathways, cytokine receptor interactions, leuko-
cyte transendothelial migration, TNFalpha/NFkB signaling,
insulin signaling and adipokine signaling (Figure 9B), clearly
demonstrating that HFD feeding suppresses baseline inflammation
in skeletal muscle. Analysis of protein expression of transcription
factors SOCS-3 and PTP1B, which have been positively
associated with IR [10,33], by Western blotting revealed a
significant increase of SOCS-3 in WAT from week 6 onward
(Figure S2). SOCS-3 protein levels remained unchanged in liver
and skeletal muscle and PTP1B protein expression levels
decreased over time in all three tissues.
Time-Resolved and Tissue-Specific Analysis of
Metabolites
To further substantiate the gene expression findings, we next
analyzed changes in the concentrations of metabolites reportedly
related to IR development within the different tissues.
The occurrence of IR in liver in week 6 was paralleled by an
increase in intrahepatic glucose concentrations, which remained
high until the end of the study (assessed by GCxGC-MS
metabolomics in livers collected under baseline, i.e. non-clamp,
conditions; Table 2). Consistent with the rapid adaptations of
carbohydrate metabolism seen at the gene level and the reduction
of endogenous HGP under baseline conditions (Figure 4B, left
panel), the intermediate metabolites of gluconeogenesis were
consistently reduced with HFD feeding (Table 2 and Figure S3).
Also, metabolites of the Krebs cycle decreased gradually over time
(Table 2).
The intrahepatic concentration of the branched chain amino
acids (BCAA) valine, leucine and isoleucine, the intake of which
can improve IR in humans [34,35], decreased over time (Table 2).
By contrast, the intrahepatic concentration of a non-BCAA,
cysteine, increased.
Fatty acid analysis of hepatic homogenates revealed that the
observed changes of lipid metabolism genes in the first 6 weeks in
liver and WAT were paralleled by pronounced changes of lipid
composition in these tissues (Table 3). For example, after 12 w of
HFD feeding, oleic acid (C18:1) was 11.2-fold (P,0.05) increased
in liver and 1.6-fold (P,0.05) increased in WAT while a-linolenic
acid (C18:3 n-3) was decreased 2.6-fold (P,0.05) in liver and 8-
fold (P,0.05) in WAT (Table S3). Of note, these changes in
hepatic lipid composition occurred already during the first 6 weeks
of HFD feeding, i.e. before significant elevations in intrahepatic
triglyceride concentrations were detected. Figure 10A/B shows
that hepatosteatosis became apparent from week 6 onward.
Parallel with the gene expression changes in WAT (for example,
enhanced lipid metabolism and increased expression of adipose
differentiation related protein, ADRP, not shown), morphological
analysis of WAT revealed a pronounced increase in adipocyte size
(hypertrophy; Figure 10C). In addition, leptin mRNA levels in
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PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8817Figure 5. Time-resolved pathway analysis for liver, WAT and muscle. Hierarchically clustered heat map of enriched functional groups of
genes (Gene Ontology). Shown are functional groups of genes that are significantly enriched in at least one time point and tissue. Clustering analysis
(Pearson correlation, complete linkage) was performed on average t-values for each time point. Red (blue) indicates up-regulation (down-regulation)
of a functional group and a positive (negative) t-value. The color intensity reflects the magnitude of a change. Columns represent the different tissues
over time and rows represent the functional clusters.
doi:10.1371/journal.pone.0008817.g005
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merely the increase in fat mass but also enhanced gene expression
is responsible for the elevated leptin levels in plasma.
Discussion
The sequence of events leading to the development of IR as well
as the risk factors and regulatory mechanisms contributing to its
pathogenesis are incompletely understood. This may be due, at
least in part, to the limitations of the animal models typically used
[36], but also to a lack of integrative, time-resolved approaches to
understand the complexity of the disease. In the present study we
used E3L mice, which exhibit a humanized lipoprotein metabo-
lism [11,37], and treated these mice with a HF diet for 12 weeks.
During this period, animals became increasingly obese (with
greatest increases in adiposity occurring after week 6), and
developed a gradual increase in glucose intolerance (by GTT)
and HOMA. Radioactive clamp analysis revealed decreased
hepatic insulin sensitivity after 6 weeks, while WAT (but not
muscle) became insulin resistant after 12 weeks, i.e. notably later
than liver (Figure 11). In a systems biology approach, we have
clarified the time-course and tissue-specificity of the underlying
metabolic adaptations (viz. carbohydrate and lipid metabolism),
pathologic consequences (e.g. change from beneficial polyunsat-
urated fatty acids to unfavourable saturated fatty acids), as well as
acute and chronic inflammatory responses.
Microarray data provide solid evidence in support of a sequence
oftime- andtissue-specific eventsduring the development ofIRafter
starting the HF diet. The liver acutely responds by up-regulating the
expressionofgenesinvolvedinglucosemetabolicprocesses,(cellular)
carbohydrate metabolic processes, fatty acid biosynthetic and
metabolic processes, (cellular) lipid metabolic processes, and lipid
transport, while in WAT only the expression of genes involved in
(cellular) lipid metabolic processes and lipid transport increase.
Strikingly, the above upregulated functional groups in liver are all
down-regulated in muscle, albeit with a slower onset.
The rapid metabolic adaptations in liver in the first week after
starting HFD (which did not affect plasma glucose or insulin levels)
coincide with an impaired ability to clear a bolus of glucose as
demonstrated in a glucose tolerance test. This phenomenon has
also been described by others [38], yet little is known about the
impact and pathologic consequences of this ‘acute’ metabolic
response.
Free fatty acid analysis further detailed the nature of the
metabolic adaptations as revealed by transcriptomics. Our data
clearly show that the content of specific IR-associated [39]
saturated and monounsaturated fatty acids increases in liver and
WAT, while, at the same time, the content of PUFAs with
beneficial effect on IR [40] decreases. Interestingly, these tissue-
specific effects were reflected by similar changes in lipid
composition in plasma. These changes cannot be detected with
standard clinical chemistry or routine lipid analyses and may
therefore have gone unnoticed in previous studies investigating
diet-induced obesity and IR. To our knowledge, our data
demonstrate for the first time and comprehensively that a change
of lipid composition in WAT and liver (and reflected in plasma)
coincide with the development of IR in these tissues. Our findings
also provide support to findings in humans indicating that specific
fatty acids are participating in the pathogenesis of IR, and that the
ratio of saturated to unsaturated fatty acids may be an important
determining factor for IR, independent of abdominal obesity
[39,41].
In humans, whole body IR depends to a great extent on muscle
IR. In the present study, skeletal muscle did not become insulin
resistant during 12 weeks of HFD feeding. There are important
differences between humans and mice regarding glucose metab-
olism in muscle. For example, the CHC22 clathrin heavy-chain
isoform is highly expressed in human skeletal muscle and plays a
key role in glucose metabolism whereas mice only express a
pseudogene for this protein [42]. Tissue-specific introduction of
CHC22 in mice caused aberrant localization of GLUT4 transport
Figure 6. Analysis of biological processes in liver, WAT and muscle over time. Response profiles of specific biological processes are shown
together with their average t-scores.
doi:10.1371/journal.pone.0008817.g006
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PLoS ONE | www.plosone.org 10 January 2010 | Volume 5 | Issue 1 | e8817Figure 7. WAT is an important source of inflammation. Comparison of the expression of prototype inflammatory genes in WAT and liver. A,
PAI-1 (Serpine1) and MCP-1 (Ccl2); B, IL-receptor antagonist (Ilm1) and C, Fibrinogen-alpha, -beta, -gamma in WAT (left) and liver (right). Data were
confirmed in independent RT-PCR analyses.
doi:10.1371/journal.pone.0008817.g007
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features of diabetes [42].
The plasma concentrations of NEFA were not markedly
affected upon HFD feeding. Development of IR is associated
with elevated plasma levels of NEFA and NEFA have long been
recognized for their contribution to decreasing insulin-mediated
glucose disposal [43]. In C57BL/6 mice (and thus also
ApoE3Leiden mice) however, NEFA typically decrease during
high fat diet feeding and this discrepancy from the human
situation has also been reported by others [44,45]. The underlying
molecular cause is not fully understood. The effect may be related
to a recent observation of Oosterveer et al.[45] who demonstrated
that HFD feeding lowers VLDL production and decreases the
relative triglyceride content of VLDL particles in C57BL/6 mice.
There is some controversy about whether hepatic IR induces
lipid accumulation in liver (hepatosteatosis) or whether hepatos-
teatosis itself is a requirement for the development of hepatic IR
[46,47]. Our finding that significant accumulation of intrahepatic
triglycerides occurs after the establishment of IR lends support to
the concept that hepatic IR precedes hepatosteatosis rather than to
the view that hepatosteatosis is a requirement for the development
of hepatic IR.
Our finding that the induction of IR by HFD is accompanied by
chronic, low-grade inflammation, as reflected by increased plasma
levels of the inflammation markers SAA, fibrinogen, VCAM-1 and
E-selectin, is in line with the notion that inflammation is crucial for
the development of IR [48]. Epidemiologists have consistently
found that chronically elevated plasma levels of systemic markers
and potential mediators of inflammation and the acute-phase
response such as C-reactive protein, fibrinogen, interleukin 6,
tumor necrosis factor-alpha (TNFa), and macrophage migration
inhibitory factor (MIF) are associated with an increased risk of
future IR [4,49], suggesting that factors that either elicit or
contribute to chronic inflammation may participate in the
pathogenesis of IR and DM2. Indeed, proinflammatory cytokines
and acute-phase reactants have been reported to be implicated in
the development of IR in humans [3,50] and in rodents [5,51,52].
The biological relevance of the activation of inflammatory
pathways in IR development is further underscored by the
demonstration that interference with these pathways can improve
or alleviate IR [3,5,6,8].
Our transcriptomics analysis adds further important new
information to the role of inflammation in the pathogenesis of
IR by specifying the time-course, tissue-specificity and nature of
the inflammatory component. This analysis shows that HFD
feeding evokes an acute-phase and a (chronic) inflammatory
response in liver and WAT, but suppresses the inflammatory state
of muscle. Importantly, the inflammatory responses in liver and
Figure 8. Chronic inflammatory processes in liver modulated by HFD. Transcriptomics data were analyzed by PathVisio with criterion
ANOVA qvalue ,0.01. Magnifications from the overall networks generated (not shown) illustrating the major inflammatory processes in liver. Red
bars indicate upregulated differentially expressed genes, green bars indicated downregulated genes. Blue nodes represent biological processes. The
insert shows the amount of active p65-NFkB in liver over time as assessed by TransAM analysis. Data are means 6 SD. *P,0.05 compared to t=0.
doi:10.1371/journal.pone.0008817.g008
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PLoS ONE | www.plosone.org 12 January 2010 | Volume 5 | Issue 1 | e8817Figure 9. Chronic inflammatory processes in WAT and muscle modulated by HFD. Transcriptomics data were analyzed by PathVisio with
criterion ANOVA qvalue ,0.01. Magnifications from the overall networks generated (not shown) illustrating the major inflammatory processes in WAT
(A) as well as the major metabolic processes of skeletal muscle (B). Red bars indicate upregulated differentially expressed genes, green bars indicated
downregulated genes. Blue nodes represent biological processes.
doi:10.1371/journal.pone.0008817.g009
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inflammatory components. Both the acute-phase and the inflam-
matory response are mainly transient in liver, while the
inflammatory responses in WAT increase over time, indicating
that WAT is an important source of inflammation in the long run.
In liver, the NFkB signaling route is moderately activated by
HFD feeding as identified by network analysis. Using a functional
p65-NFkB-binding assay (TransAM) we showed an increase in
NF-kB activity during HFD feeding in week 6, i.e. the time point
at which the liver became insulin resistant. This observations is in
agreement with data from others showing that already slight
elevations in hepatic NF-kB activity can cause liver IR [8]. We also
found an increase in SOCS-3 protein expression in WAT from
week 6 onward. This effect may contribute to IR in WAT as
overexpression of SOCS-3 in adipose tissue [53], liver [10] or
skeletal muscle [54] caused local IR.
The chronic inflammatory response of WAT involves an
increased expression of the genes encoding for interleukin-1
receptor antagonist, CCL2/MCP-1 and PAI-1. Others have
shown that interleukin-1 receptor antagonist is overexpressed in
WAT of obese humans [55] and that CCL2/MCP-1 contributes
to adipose IR and the development hepatic steatosis [6]. Indeed, in
the present study, the development of WAT-specific IR and
hepatosteatosis parallels the expression of Ccl2/Mcp-1. The
pronounced increase in PAI-1 gene expression may be explained
by the observation that the expression of Ppar-gamma, a negative
regulator of Pai-1 transcription [56] is reduced by HFD feeding.
Remarkably, comparison of liver and WAT revealed that genes
encoding for SAA, PAI-1, MCP-1 and fibrinogen-a,-b and-c were
predominantly and almost exclusively increased in WAT. The
plasma inflammation markers, SAA and fibrinogen, are generally
viewed as being biosynthesized in liver [57]. Our observation that
the concentrations of SAA and fibrinogen are gradually and
continuously increasing over the 12-week HFD feeding period
would suggest that ‘subacute hepatic inflammation’ might be
involved in the onset and development of IR. However, contrary
to existing views, transcriptomics analysis indicated that the
increased SAA and fibrinogen expression occurred in WAT, and
not liver. While adipose expression of SAA is well-established [58],
fibrinogen a, b and c gene expression in WAT has not been
demonstrated so far.
Together, the present study uses an integrative approach to
gain insight into the tissue-specificity and time-course of metabolic
and inflammatory processes that underlie the development of
HFD-induced IR in a humanized mouse model, E3L mice.
Notably, the observed effects can mainly be ascribed to HFD
feeding rather than to aging as with chow feeding alone no
inflammation or insulin resistance develops within a period of 12
weeks [59]. The data show that both liver and WAT rapidly
respond to HFD by metabolic adaptations and inflammatory
responses that lead to IR, first in liver and subsequently also in
WAT. The biochemical pathways affected are numerous and
different for the various tissues, indicating that the design of
effective treatment regimens should be at an integral level rather
than directed at a single target.
Table 2. Intrahepatic metabolites.
t=0 6w 12w
Gluconeogenesis
Pyrophosphate 100639 79630 3468*
Phosphoenol-PP 100654 89641 57622
Fructose-6-phosphate 100645 71632 62623*
Glucose-6-phosphate 100629 83631 54627*
Glucose 100628 144663 1876106*
Krebs Cycle
Succinic acid 100626 91625 81619
Fumaric acid 100640 5267* 4166*
Citric acid 100627 66613* 4669*
Branched chain amino acids
L-Leucine 1006 89621 69626*
L-Valine 100622 86632 66618*
L-Isoleucine 100629 83610 61618*
L-Cysteine 100691 4 3 631* 112627
The effect of HFD feeding on intrahepatic metabolites was assessed by GCxGC-
MS-based metabolomics analysis using liver tissue biopsies. The same livers that
were used for microarray analysis were analyzed. Data are presented as relative
changes in metabolite levels over time with t=0 set 100% and as means 6 SD.
*P,0.05 compared to t=0.
doi:10.1371/journal.pone.0008817.t002
Table 3. Intrahepatic saturated, monounsaturated and
polyunsaturated fatty acids.
Intrahepatic saturated fatty acids
weeks 0 6 12
myristic acid C14:0 0.2660.05 0.7260.20 1.3260.47*
palmitic acid C16:0 6.061.3 12.563.8 23.869.1
stearic acid C18:0 1.760.2 2.960.3 3.460.8*
eicosanoic acid C20:0 0.0760.02 0.1360.04 0.3260.10*
behenic acid C22:0 0.02060.004 0.01960.003 0.04060.008*
Intrahepatic monounsaturated fatty acids
weeks 0 6 12
palmitoleic acid C16:1 0.8360.25 2.2760.86 4.1861.61*
oleic acid C18:1 3.961.2 19.567.2 43.5617.0*
eicosenic acid C20:1 0.1560.5 0.8860.33 2.6260.94*
erucic acid C22:1 0.0260.01 0.0660.02 0.2060.07*
Intrahepatic polyunsaturated fatty acids n-3 PUFAs
weeks 0 6 12
a-linolenic acid C18:3 n-3 0.1860.05 0.0660.02* 0.0760.03*
stearidonic acid C18:4 n-3 0.01360.003 0.00660.002* 0.00360.001*
eicosatetraenoic acid C20:4 n-3 0.06060.009 0.06660.007 0.05660.009
EPA; eicosapentaenoic
acid
C20:5n-3 0.04860.005 0.04360.005 0.02860.005*
DHA; docosahexaenoic
acid
C22:6n-3 0.7060.12 0.7660.05 0.6360.08
Intrahepatic polyunsaturated fatty acids n-6 PUFAs
weeks 0 6 12
linoleic acid C18:2 n-6 3.4760.87 1.1860.56 2.3160.80
gamma-linolenic acid C18:3 n-6 0.0960.02 0.0660.02 0.0560.02
dihomo-c-linolenic acid C20:3 n-6 0.0160.00 0.4260.06* 0.576.013*
arachidonic acid C20:4 n-6 0.9860.16 1.0260.07 0.8760.11
adrenic acid C22:4 n-6 0.0560.01 0.0660.02 0.0660.01
Quantitative LC/MS analysis of defined fatty acids in tissue homogenates of liver
(comparable effects were seen for WAT; not shown). Data are presented as
relative units and provided as means 6 SEM. *P,0.05 compared to t=0. Livers
of the same animals used for microarray analysis were analyzed.
doi:10.1371/journal.pone.0008817.t003
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PLoS ONE | www.plosone.org 14 January 2010 | Volume 5 | Issue 1 | e8817Figure 10. HFD feeding causes hepatosteatosis and WAT hypertrophy. (A) Representative photomicrographs of Oil Red O-stained liver
cross-sections at t=0 (i), week 6 (ii) and week 12 (iii). (B) Analysis of intrahepatic triglycerides. Values are mean 6 SEM *P,0.01 vs t=0, **P,0.001 vs
t=0. (C) HPS-stained epididymal adipose tissue at t=0 (i) and week 12 (ii). Biopsies from tissues also analyzed by microarray were used. Bars indicate
100 mm. (D) Leptin expression over time.
doi:10.1371/journal.pone.0008817.g010
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Table S1 Diet composition of the high-fat diet used.
Found at: doi:10.1371/journal.pone.0008817.s001 (0.10 MB
PDF)
Table S2 Saturated, monounsaturated, and polyunsaturated
fatty acids in plasma.
Found at: doi:10.1371/journal.pone.0008817.s002 (0.06 MB
PDF)
Table S3 Saturated, monounsaturated, and polyunsaturated
fatty acids in white adipose tissue.
Found at: doi:10.1371/journal.pone.0008817.s003 (0.06 MB
PDF)
Figure S1 Targeted analysis of genes in pathways. The gene
expression changes of glycolysis and gluconeogenesis genes are
shown for liver, muscle, and white adipose tissue. Individual gene
expression was statistically compared to the expression level at t
=0, and coloring indicates fold change and significance (green =
significant in ANOVA; P#.01).
Found at: doi:10.1371/journal.pone.0008817.s004 (0.41 MB
PDF)
Figure S2 Western blot analysis of SOCS-3 and PTP1B protein
expression in liver, white adipose tissue, and muscle over time.
*P,0.05 compared to t =0.
Found at: doi:10.1371/journal.pone.0008817.s005 (0.03 MB
PDF)
Figure S3 Metabolites of gluconeogenesis.
Found at: doi:10.1371/journal.pone.0008817.s006 (0.37 MB TIF)
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